Horizon Therapeutics' Daxdilimab Trial Falls Short on Primary Endpoint
- July 23rd, 2023
- 486 views
Horizon Therapeutics plc (Nasdaq: HZNP) reported disappointing results from its Phase 2 clinical trial for daxdilimab in the treatment of systemic lupus erythematosus (SLE), the most common type of lupus. The trial did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which measured low SLE disease activity.
However, the company reported numerical differences in other endpoints and stated that there were no safety concerns. Horizon Therapeutics remains committed to assessing the full dataset. The company's daxdilimab trials in alopecia areata, discoid lupus erythematosus, and lupus nephritis are still ongoing.
Following the announcement, $HZNP declined by $1.18 (-1.17%) to $100.00 in after-hours trading on Friday.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login